Search

Search Constraints

You searched for: Author/Creator Munder, Markus

Search Results

1. A drug repurposing approach for individualized cancer therapy based on transcriptome sequencing and virtual drug screening. (May 2023)

2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022)

3. Granulocyte functions are independent of arginine availability. Issue 6 (7th August 2014)

4. Granulocyte functions are independent of arginine availability. Issue 6 (7th August 2014)

5. Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. (8th February 2021)

6. Induced arginine transport via cationic amino acid transporter‐1 is necessary for human T‐cell proliferation. Issue 1 (2nd November 2015)

7. Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. Issue 4 (21st March 2022)

8. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. Issue 8 (22nd November 2022)

10. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. (3rd October 2018)